Skip to main content
Erschienen in: Annals of Surgical Oncology 8/2007

01.08.2007 | Gastrointestinal Oncology

Surgical Management and Outcome in Primary Adenocarcinoma of the Small Bowel

verfasst von: Shefali Agrawal, MD, Edward C. McCarron, MD, John F. Gibbs, MD, Hector R. Nava, MD, Gregory E. Wilding, PhD, Ashwani Rajput, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 8/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

Primary adenocarcinoma of the small bowel is a rare malignancy and is associated with poor survival outcome. Patient, tumor and treatment-related factors were analyzed for their association with recurrence and survival.

Methods

Between 1971 and 2005, 64 patients with primary adenocarcinoma of the small bowel were treated at our institution. Clinico-pathologic data, operative details, postoperative treatment, recurrence pattern and survival were reviewed.

Results

The most common clinical features at presentation included abdominal pain (n = 33; 51.6%) or bowel obstruction (n = 20; 31.3%). The most frequently involved portion of the small bowel was the duodenum (n = 41; 64%). A segmental bowel resection was performed in 30 patients and pancreaticoduodenectomy in 14 patients. Postoperative mortality and morbidity rates were 3.6% (n = 2) and 14.5% (n = 8), respectively. Of the 55 patients who underwent operative intervention, a curative resection was performed in 30 (54.5%). The most common sites of recurrence following a curative resection were the liver and lung. Median survival for all 64 patients was 18 months with a 5-year survival of 21.1%. On multivariate analysis, absence of distant metastatic disease (5-year survival 30.4%), curative resection (5-year survival 44.8%) and pathological T stage 1-3 (5-year survival 39.2%) were identified as independent predictors of survival.

Conclusions

A curative resection in the absence of both distant metastases and pathological T4 tumor provides the best survival outcome. Recurrence at distant sites is the predominant pattern of failure following a curative resection, suggesting a role for adjuvant therapy.
Literatur
1.
Zurück zum Zitat Howe JR, Karnell LH, Menck HR, Scott-Conner C. Adenocarcinoma of the small bowel. Review of the National Cancer Data Base 1985–1995. Cancer 1999; 86:2693–2706PubMedCrossRef Howe JR, Karnell LH, Menck HR, Scott-Conner C. Adenocarcinoma of the small bowel. Review of the National Cancer Data Base 1985–1995. Cancer 1999; 86:2693–2706PubMedCrossRef
2.
Zurück zum Zitat Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J. Adenocarcinoma of the small bowel. Presentation, prognostic factors and outcome of 217 patients. Cancer 2004; 101:518–526PubMedCrossRef Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J. Adenocarcinoma of the small bowel. Presentation, prognostic factors and outcome of 217 patients. Cancer 2004; 101:518–526PubMedCrossRef
3.
Zurück zum Zitat Bauer RL, Palmer ML, Bauer AM, Nava HR, Douglass HO. Adenocarcinoma of the small intestine: 21-year review of diagnosis, treatment and prognosis. Ann Surg Oncol 1994; 1(3):183–188PubMedCrossRef Bauer RL, Palmer ML, Bauer AM, Nava HR, Douglass HO. Adenocarcinoma of the small intestine: 21-year review of diagnosis, treatment and prognosis. Ann Surg Oncol 1994; 1(3):183–188PubMedCrossRef
4.
Zurück zum Zitat Ito H, Perez A, Brooks DC, et al. Surgical treatment of small bowel cancer: a 20-year single institution experience. J Gastrointest Surg 2003; 7:925–930PubMedCrossRef Ito H, Perez A, Brooks DC, et al. Surgical treatment of small bowel cancer: a 20-year single institution experience. J Gastrointest Surg 2003; 7:925–930PubMedCrossRef
5.
Zurück zum Zitat Cunningham JD, Aleali R, Aleali M, Brower ST, Aufses AH. Malignant small bowel neoplasms: histopathologic determinants of recurrence and survival. Ann Surg 1997; 225(3):300–306PubMedCrossRef Cunningham JD, Aleali R, Aleali M, Brower ST, Aufses AH. Malignant small bowel neoplasms: histopathologic determinants of recurrence and survival. Ann Surg 1997; 225(3):300–306PubMedCrossRef
6.
Zurück zum Zitat Frost DB, Mercado PD, Tyrell JS. Small bowel cancer: a 30-year review. Ann Surg Oncol 1994; 1(4):290–295PubMedCrossRef Frost DB, Mercado PD, Tyrell JS. Small bowel cancer: a 30-year review. Ann Surg Oncol 1994; 1(4):290–295PubMedCrossRef
7.
Zurück zum Zitat Zollinger RM, Sternfeld WC, Schreiber H. Primary neoplasms of the small intestine. Am J Surg 1986; 15:654–658CrossRef Zollinger RM, Sternfeld WC, Schreiber H. Primary neoplasms of the small intestine. Am J Surg 1986; 15:654–658CrossRef
8.
Zurück zum Zitat Naef M, Buhlmann M, Baer HU. Small bowel tumors: diagnosis, therapy and prognostic factors. Langenbecks Arch Surg 1999; 384:176–180PubMedCrossRef Naef M, Buhlmann M, Baer HU. Small bowel tumors: diagnosis, therapy and prognostic factors. Langenbecks Arch Surg 1999; 384:176–180PubMedCrossRef
9.
Zurück zum Zitat Awrich AE, Irish CE, Vetto RM, Fletcher WS. A twenty-five year experience with primary malignant tumors of the small intestine. Surg Gynecol Obstet 1980; 151:9–14PubMed Awrich AE, Irish CE, Vetto RM, Fletcher WS. A twenty-five year experience with primary malignant tumors of the small intestine. Surg Gynecol Obstet 1980; 151:9–14PubMed
10.
Zurück zum Zitat Santoro E, Sacchi M, Scutari F, Carboni F, Grazioni F. Primary adenocarcinoma of the duodenum: treatment and survival in 89 patients. Hepatogastroenterology 1997; 44:1157–1163PubMed Santoro E, Sacchi M, Scutari F, Carboni F, Grazioni F. Primary adenocarcinoma of the duodenum: treatment and survival in 89 patients. Hepatogastroenterology 1997; 44:1157–1163PubMed
11.
Zurück zum Zitat Sohn TA, Lillemoe KD, Cameron JL, Pitt HA, Kaufman HS, Hruban RH, Yeo CJ. Adenocarcinoma of the duodenum: Factors influencing long-term survival. J Gastrointest Surg 1998; 2:79–87PubMedCrossRef Sohn TA, Lillemoe KD, Cameron JL, Pitt HA, Kaufman HS, Hruban RH, Yeo CJ. Adenocarcinoma of the duodenum: Factors influencing long-term survival. J Gastrointest Surg 1998; 2:79–87PubMedCrossRef
12.
Zurück zum Zitat Bakaeen FG, Murr M, Sarr MG, et al. What prognostic factors are important in duodenal adenocarcinoma. Arch Surg 2000; 135(6):635–642PubMedCrossRef Bakaeen FG, Murr M, Sarr MG, et al. What prognostic factors are important in duodenal adenocarcinoma. Arch Surg 2000; 135(6):635–642PubMedCrossRef
13.
Zurück zum Zitat Veyrieres M, Baillet P, Hay JM, Fingerhut A, Bouillot JL, Julien M. factors influencing long-term survival in 100 cases of small intestine primary adenocarcinoma. Am J Surg 1997; 173:237–239PubMedCrossRef Veyrieres M, Baillet P, Hay JM, Fingerhut A, Bouillot JL, Julien M. factors influencing long-term survival in 100 cases of small intestine primary adenocarcinoma. Am J Surg 1997; 173:237–239PubMedCrossRef
14.
Zurück zum Zitat Barnes G, Romero L, Hess KR, Curley SA. Primary adenocarcinoma of the duodenum: management and survival in 67 patients. Ann Surg Oncol 1994; 1(1):73–78PubMedCrossRef Barnes G, Romero L, Hess KR, Curley SA. Primary adenocarcinoma of the duodenum: management and survival in 67 patients. Ann Surg Oncol 1994; 1(1):73–78PubMedCrossRef
15.
Zurück zum Zitat Brucher BLDM, Stein HJ, Roder JD, Busch R, Fink U, Werner M, Siewert JR. New aspects of prognostic factors in adenocarcinomas of the small bowel. Hepatogastroenterology 2001; 48:727–732PubMed Brucher BLDM, Stein HJ, Roder JD, Busch R, Fink U, Werner M, Siewert JR. New aspects of prognostic factors in adenocarcinomas of the small bowel. Hepatogastroenterology 2001; 48:727–732PubMed
16.
Zurück zum Zitat Lambert P, Minghini A, Pincus W, Kolm P, Perry RR. Treatment and prognosis of primary malignant small bowel tumors. Am Surg 1996; 62(9):709–715PubMed Lambert P, Minghini A, Pincus W, Kolm P, Perry RR. Treatment and prognosis of primary malignant small bowel tumors. Am Surg 1996; 62(9):709–715PubMed
17.
Zurück zum Zitat Chow JS, Chen CC, Ahsan H, Neugut AI. A population-based study of the incidence of malignant small bowel tumors: SEER, 1973–1990. Int J Epidemiol 1996; 25:722–728PubMedCrossRef Chow JS, Chen CC, Ahsan H, Neugut AI. A population-based study of the incidence of malignant small bowel tumors: SEER, 1973–1990. Int J Epidemiol 1996; 25:722–728PubMedCrossRef
18.
Zurück zum Zitat Stell D, Mayer D, Mirza D, Buckels J. Delayed diagnosis and lower resection rate of adenocarcinoma of the distal duodenum. Dig Surg 2004; 21:434–439PubMedCrossRef Stell D, Mayer D, Mirza D, Buckels J. Delayed diagnosis and lower resection rate of adenocarcinoma of the distal duodenum. Dig Surg 2004; 21:434–439PubMedCrossRef
19.
Zurück zum Zitat Maglinte DDT, O’Connor K, Bessette J, Chernish SM, Kelvin FM. The role of the physician in the late diagnosis of primary malignant tumors of the small intestine. Am J Gastroenterol 1991; 86(3):304–308PubMed Maglinte DDT, O’Connor K, Bessette J, Chernish SM, Kelvin FM. The role of the physician in the late diagnosis of primary malignant tumors of the small intestine. Am J Gastroenterol 1991; 86(3):304–308PubMed
20.
Zurück zum Zitat Fishman PN, Pond GR, Moore MJ, et al. Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases. Am J Clin Oncol 2006; 29(3):225–231PubMedCrossRef Fishman PN, Pond GR, Moore MJ, et al. Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases. Am J Clin Oncol 2006; 29(3):225–231PubMedCrossRef
21.
Zurück zum Zitat Locher C, Malka D, Boige V, Lebray P, Elias D, Lasser P, Ducreux M. Combination chemotherapy in advanced small bowel adenocarcinoma. Oncology 2005; 69(4):290–294PubMedCrossRef Locher C, Malka D, Boige V, Lebray P, Elias D, Lasser P, Ducreux M. Combination chemotherapy in advanced small bowel adenocarcinoma. Oncology 2005; 69(4):290–294PubMedCrossRef
Metadaten
Titel
Surgical Management and Outcome in Primary Adenocarcinoma of the Small Bowel
verfasst von
Shefali Agrawal, MD
Edward C. McCarron, MD
John F. Gibbs, MD
Hector R. Nava, MD
Gregory E. Wilding, PhD
Ashwani Rajput, MD
Publikationsdatum
01.08.2007
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 8/2007
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9428-2

Weitere Artikel der Ausgabe 8/2007

Annals of Surgical Oncology 8/2007 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.